Healthcare ratings roundup - new coverage #1

• Adamas Pharmaceuticals (ADMS +7.5%) initiated with Market Outperform rating and $29 (86% upside) price target by JMP Securities.
• Amsurg (AMSG +0.2%) initiated with Buy rating and $84 (12% upside) price target by Mizuho Securities.
• Syndax Pharmaceuticals (SNDX -0.2%) initiated with Outperform rating and $24 (92% upside) price target by Oppenheimer.
• Ardelyx (ARDX) initiated with Buy rating and $21 (167% upside) price target by Ladenburg Thalmann.
• Illumina (ILMN +2.1%) initiated with a Buy rating and $175 (5% upside) price target by Argus Research.
• Seres Therapeutics (MCRB -1.3%) initiated with Outperform rating and $40 (56% upside) price target by FBR Capital.
• Intercept Pharmaceuticals (ICPT -0.2%) initiated with Neutral rating and $114 (12% downside risk) price target by Goldman Sachs. Initiated with Outperform rating and $200 (54% upside) price target by Credit Suisse.
• Agios Pharmaceuticals (AGIO +2.4%) initiated with Buy rating and $57 (36% upside) price target by SunTrust Robinson Humphrey.
• SAGE Therapeutics (SAGE +0.5%) initiated with Buy rating and $63 (95% upside) price target by Goldman Sachs.
• Acorda Therapeutics (ACOR +1.2%) initiated with Sell rating and $23 (14% downside risk) price target by Goldman Sachs.